CD47 blockade has remarkable therapeutic efficacy in various preclinical models of bladder, colon and breast cancer, glioblastoma, lymphoma, and acute lymphocytic leukemia (Jaiswal et al,2009; Willingham et al,2012; Liu et al,2015). Here, CD47 is linked to glioblastoma.